Interventional {{label}}

Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Overview

Intervention or Drug Name

Sponsor

Trial Status

Phase

Randomization

Trial Duration

Route of Administration

Genetic Target

Repurposed Drugs

Approved by FDA

Approved outside USA

Is a supplement

Details

Enrollment Criteria

Time since symptom onset

Vital Capacity (FVC or SVC)

Approved Medications

Registry Listing

{{trial.ExternalId}} (First Published: {{trial.FirstPublishedDate|date}} on {{trial.SourceName}})

Purpose

By doing this study, researchers hope to learn if rasagiline is safe and slows disease progression in patients with ALS.

What participation looks like

Participants will take 2mg rasagiline daily for 12 months or placebo for 12 months and then 2mg rasagiline for 12 months. Primary outcome is ALS-FRS. Secondary outcomes include changes in vital capacity and quality of life.

Eligibility criteria

People 21-80 yrs of age with laboratory-supported probable, probable, or definite ALS. No healthy volunteers.

Locations

{{location.City !== '' ? location.City + ',' : ''}} {{location.RegionAbbreviation}} {{location.PostalCode}} {{location.Country}}

{{location.Facility !== '' ? location.Facility + ',' : ''}} {{location.City !== '' ? location.City + ',' : ''}} {{location.RegionAbbreviation}} {{location.PostalCode}} {{location.Country}}

Location Contact: {{location.Contact.Name}} {{location.Contact.Name}} Phone: {{location.Contact.Phone}}

Join the ALS Research Collaborative (ARC) Study Today!

Ready to make a difference in ALS research?

Join the ARC Study! Whether you're living with ALS or an asymptomatic gene carrier, your participation can help inform ALS research and lead to new treatments.

Learn More

Thank You to Our Sponsors